(Q72077055)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

title

Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

1 reference

acute myeloid leukemia

1 reference

A Heyll

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

C Aul

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

F Gogolin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

V Runde

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

D Söhngen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

G Meckenstock

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

H H Wolf

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

J Zahner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

M Burk

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

M Winkelmann

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

publication date

1 June 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

page(s)

279-283

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

23 October 2019

cites work

1 reference

12 December 2020

How to improve therapy for adult acute myeloid leukemia: studies of the AML Cooperative Group in the Federal Republic of Germany

1 reference

12 December 2020

Cardiovascular effects of doxorubicin (Adriamycin) and 4-demethoxydaunorubicin (Idarubicin) in the conscious rat.

1 reference

12 December 2020

Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases

1 reference

12 December 2020

Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy

1 reference

12 December 2020

Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

1 reference

12 December 2020

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

1 reference

12 December 2020

Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol)

1 reference

12 December 2020

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

1 reference

12 December 2020

Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent

1 reference

12 December 2020

Treatment of acute myelogenous leukemia in the elderly

1 reference

12 December 2020

The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome

1 reference

12 December 2020

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

12 December 2020

A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia

1 reference

12 December 2020

Treatment of acute myeloid leukemia in elderly patients. A retrospective study.

1 reference

12 December 2020

Low-dose cytosine arabinoside in patients with acute myeloblastic leukemia and myelodysplastic syndrome

1 reference

12 December 2020

High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01695033

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8038233%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

1 reference